H. Lundbeck A/S
H. Lundbeck A/S (HLBBF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hlbbf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
H. Lundbeck A/SYou HLBBF | $5.8B | N/A | — | — |
 Sumitomo Pharma Co., Ltd. DNPUF | $4.7B | 7.96x | -32.8% | $270.68 |
 Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited GZPHF | $6.2B | 8.37x | -29.3% | $1.79 |
 Hikma Pharmaceuticals PLC HKMPF | $4.1B | 11.24x | -5.1% | $1.86 |
 Hikma Pharmaceuticals PLC HKMPY | $4.3B | 11.48x | -3.1% | $3.65 |
 Livzon Pharmaceutical Group Inc. LVZPF | $5.1B | 16.54x | +39.7% | $2.21 |
 Ono Pharmaceutical Co., Ltd. OPHLF | $6.8B | 15.45x | +30.5% | $149.42 |
Industry Average 6 peers with valid PE | — | 11.84x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for H. Lundbeck A/S (HLBBF) measures how much investors pay for each dollar of the company's trailing earnings. HLBBF's current PE ratio of N/A is calculated by dividing its stock price of $7.29 by its TTM earnings per share of —.
Frequently asked questions
HLBBF pe ratio · 6 questionsHLBBF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $7.29 and TTM EPS of —. Data sourced from Financial Modeling Prep via HLBBF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · H. Lundbeck A/S SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09